Aprea Therapeutics, Inc. Stock Price, News & Analysis

Aprea Therapeutics (Nasdaq: APRE) reported its Q3 2020 financial results and business updates, focusing on its lead product candidate, eprenetapopt. The company has completed enrollment in pivotal Phase 3 trials for TP53 mutant MDS with azacitidine and is enhancing its clinical pipeline in AML and solid tumors. As of September 30, 2020, Aprea had $101.1 million in cash, down from $130.1 million at 2019 year-end, and anticipates a cash burn of $35-40 million for 2020. The net loss for Q3 2020 was $12.3 million, or $0.58 per share, compared to $6.2 million in Q3 2019.

Aprea Therapeutics (Nasdaq: APRE) hosted a virtual R&D Day Webinar on October 30, 2020, featuring discussions by experts in hematology regarding clinical therapies for TP53 mutant MDS/AML patients. The agenda included a review of Aprea's Phase 3 clinical program and commercial strategies. Aprea's lead candidate, eprenetapopt, targets mutant tumor suppressor protein p53 and has received multiple FDA designations for MDS. The company is developing APR-548 as a next-generation agent with a planned Phase 1 trial. For more information, visit Aprea's website.

Aprea Therapeutics, Inc. (Nasdaq: APRE) has launched p53reactivation.com to enhance disease awareness regarding p53 mutations in cancer. This initiative aims to educate healthcare professionals on how these mutations are linked to poor treatment outcomes. With approximately half of all cancers featuring p53 mutations, the site seeks to promote understanding of diagnostic tests and potential targeted therapies, marking a significant step in addressing this unmet medical need.

Aprea Therapeutics (NASDAQ: APRE) announced FDA acceptance of its IND application for APR-548, targeting TP53 mutant myelodysplastic syndromes (MDS). This milestone is crucial for the next-generation small molecule aimed at reactivating mutant p53. CEO Christian S. Schade expressed optimism about initiating a Phase 1 clinical trial for APR-548, reinforcing Aprea's commitment to advancing therapeutic options for p53 mutated cancers. The company is also progressing with its lead product, eprenetapopt, which has received multiple FDA designations for MDS and other malignancies.

Aprea Therapeutics (NASDAQ: APRE) announced the addition of Michael A. Kelly to its Board of Directors, where he will be part of the audit and governance committees. With over 20 years in life sciences, Kelly has held senior roles at Amgen and founded Sentry Hill Partners. His expertise is expected to enhance Aprea's mutant p53 reactivator oncology programs aimed at commercialization. The company focuses on developing innovative cancer therapies, including APR-246, which has received several FDA designations for hematologic malignancies.

Aprea Therapeutics (NASDAQ: APRE) announced the appointment of Michael A. Kelly to its Board of Directors, who brings over 20 years of life sciences leadership. Kelly's experience includes senior roles at Amgen and his own consulting firm, Sentry Hill Partners. He will serve on the audit and governance committees. His financial and operational expertise is expected to bolster Aprea's efforts in advancing its mutant p53 reactivator oncology programs, particularly APR-246, which is in clinical development for various cancers.

Aprea Therapeutics (NASDAQ: APRE) announced the promotion of Gregory S. Wessels to Chief Commercial Officer. This move is timely as the company approaches significant milestones in its frontline MDS program and continues developing eprenetapopt. Wessels brings extensive oncology experience from Bristol-Myers Squibb. Additionally, independent directors Scott Rocklage, Ph.D., and Jonathan Hepple, Ph.D., will step down from the Board after nearly a decade. The company has received multiple FDA designations for eprenetapopt, its lead candidate targeting mutant p53, crucial for cancer therapy.

Aprea Therapeutics (NASDAQ: APRE) announced the appointments of Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to its Board of Directors, effective June 30, 2020. Dr. Namouni has over 20 years in oncology development, previously at Bristol-Myers Squibb, while Dr. Peters brings 25 years of experience from roles at Yumanity and Merrimack Pharmaceuticals. Their expertise is expected to bolster Aprea's mutant p53 reactivator oncology programs. Guido Magni, M.D., Ph.D. is stepping down from the Board. Aprea focuses on developing cancer therapeutics, particularly APR-246 for hematologic malignancies.

Aprea Therapeutics (Nasdaq: APRE) presented updated data from its Phase 1b/2 clinical trial of APR-246 combined with azacitidine for TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) at the EHA Annual Meeting. The trial showed a 75% overall response rate (ORR) and a 57% complete remission (CR) rate in evaluable MDS patients. The median overall survival (OS) was 12.1 months across all patients and improved to 13.7 months for those receiving 3 or more cycles. The results indicate significant therapeutic potential for high-risk MDS and AML patients.